Laura A Scott1, Thomas R Berni1, Ellen R Berni1, Jane De Vries2, Craig J Currie1,3. 1. a Global Epidemiology, Pharmatelligence , Cardiff , UK. 2. b Independent consultant to Aimmune Therapeutics Inc ., London , UK. 3. c The Institute of Population Medicine, School of Medicine, Cardiff University , Cardiff , UK.
Abstract
Aims: We aimed to estimate the resource use and associated costs for patients with peanut allergy (PA) compared to matched controls. Methods: This was a retrospective cohort study using data from the UK Clinical Practice Research Datalink and Hospital Episode Statistics. PA patients were matched to two control cohorts: the first (simple-matched) were matched 1:1 on year of birth, general practice, gender and registration year. The second (atopy-matched) were matched on the same characteristics plus presence/absence of an atopic condition. Prescriptions and primary and secondary care contacts were compared between cases and controls. Results: 15,483 peanut-allergic patients were identified: 13,609 (87.9%) were simple-matched and 9,320 (60.2%) atopy-matched. The total per person annual incremental health-care costs associated with PA were £253 (atopy-matched) and £333 (simple-matched). For those with PA and a prior anaphylaxis incremental costs were £662, for those prescribed an epinephrine autoinjector incremental costs were £392. Extrapolated to the U.K. population, total excess costs of PA were between £33 and 44 million in 2015. Conclusions: Patients with PA had increased health-care contacts and consequently increased associated costs compared to controls. Observation bias should be considered in interpretation, but this study suggests that PA presents significant burden to health-care systems.
Aims: We aimed to estimate the resource use and associated costs for patients with peanutallergy (PA) compared to matched controls. Methods: This was a retrospective cohort study using data from the UK Clinical Practice Research Datalink and Hospital Episode Statistics. PA patients were matched to two control cohorts: the first (simple-matched) were matched 1:1 on year of birth, general practice, gender and registration year. The second (atopy-matched) were matched on the same characteristics plus presence/absence of an atopic condition. Prescriptions and primary and secondary care contacts were compared between cases and controls. Results: 15,483 peanut-allergicpatients were identified: 13,609 (87.9%) were simple-matched and 9,320 (60.2%) atopy-matched. The total per person annual incremental health-care costs associated with PA were £253 (atopy-matched) and £333 (simple-matched). For those with PA and a prior anaphylaxis incremental costs were £662, for those prescribed an epinephrine autoinjector incremental costs were £392. Extrapolated to the U.K. population, total excess costs of PA were between £33 and 44 million in 2015. Conclusions: Patients with PA had increased health-care contacts and consequently increased associated costs compared to controls. Observation bias should be considered in interpretation, but this study suggests that PA presents significant burden to health-care systems.
Entities:
Keywords:
Peanut; allergy; anaphylaxis; costs; healthcare resource use
Authors: Lars Lange; Ludger Klimek; Kirsten Beyer; Katharina Blümchen; Natalija Novak; Eckard Hamelmann; Andrea Bauer; Hans Merk; Uta Rabe; Kirsten Jung; Wolfgang Schlenter; Johannes Ring; Adam Chaker; Wolfgang Wehrmann; Sven Becker; Norbert Mülleneisen; Katja Nemat; Wolfgang Czech; Holger Wrede; Randolf Brehler; Thomas Fuchs; Thilo Jakob; Tobias Ankermann; Sebastian M Schmidt; Michael Gerstlauer; Torsten Zuberbier; Thomas Spindler; Christian Vogelberg Journal: Allergo J Int Date: 2021-09-28